Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 9673537, 21 pages
https://doi.org/10.1155/2017/9673537
Review Article

Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation

1Verra Therapeutics, 127 Asbury Rd., Lansing, NY 14882, USA
2Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR 6th Floor, Fort Lauderdale, FL 33328, USA
3College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA

Correspondence should be addressed to Marcia L. Moss

Received 4 July 2017; Revised 15 August 2017; Accepted 11 September 2017; Published 2 November 2017

Academic Editor: Vera L. Petricevich

Copyright © 2017 Marcia L. Moss and Dmitry Minond. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation.